Clinical pharmacology and efficacy of rotigotine (Neupro® patch) in the treatment of restless leg syndrome

References

• Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome/Willis–Ekbom disease diagnostic criteria: updated international restless legs syndrome study group (IRLSSG) consensus criteria–history, rationale, description, and significance. Sleep Med. 2014;15:860–873.
   PubMed Web of Science ®Google Scholar
• Ohayon MM, O’Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev. 2012;16:283–295.
   PubMed Web of Science ®Google Scholar
• Picchietti D, Allen RP, Walters AS, et al. Restless legs syndrome: prevalence and impact in children and adolescents- the Peds REST study. Pediatrics. 2007;120:253–266.
   PubMed Web of Science ®Google Scholar
• Silber MH, Becker PM, Earley C, et al. Willis–Ekbom disease foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc. 2013;88:977–986.
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome/Willis–Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the international restless legs syndrome study group. Sleep Med. 2013;14:675–684.
   PubMed Web of Science ®Google Scholar
• Silver N, Allen RP, Senerth J, et al. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med. 2011;12:440–444.
   PubMed Web of Science ®Google Scholar
• Oertel W, Trenkwalder C, Benes H, et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol. 2011;10:710–720.
   PubMed Web of Science ®Google Scholar
• Maestri M, Fulda S, Ferini-Strambi L, et al. Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis–Ekbom disease. Sleep Med. 2014;15:570–575.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Swope DM, Dashtipour K, et al. Transdermal rotigotine: a clinically innovative dopamine‐receptor agonist for the management of Parkinson’s disease. Pharmacotherapy. 2009;29:1452–1467.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Winkelmann J, Inoue Y, et al. Restless legs syndrome-current therapies and management of augmentation. Nat Rev Neurol. 2015;11:434–445.
   PubMed Web of Science ®Google Scholar
• Scheller D, Ullmer C, Berkels R, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. NaunynSchmiedebergs Arch Pharmacol. 2009;379:73–86.
   PubMed Web of Science ®Google Scholar
• Elshoff JP, Braun M, Andreas JO, et al. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. ClinTher. 2012;34:966–978.
   Google Scholar
• Benitez A, Edens H, Fishman J, et al. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson’s disease and restless legs syndrome. Ann N Y Acad Sci. 2014;1329:45–66.
   PubMed Web of Science ®Google Scholar
• Tzonova D, Larrosa O, Calvo E, et al. Breakthrough symptoms during the daytime in patients with restless legs syndrome (Willis–Ekbom disease). Sleep Med. 2012;13:151–155.
   PubMed Web of Science ®Google Scholar
• Elshoff JP, Cawello W, Andreas JO, et al. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson’s disease and restless legs syndrome. Drugs. 2015;75:487–501.
   PubMed Web of Science ®Google Scholar
• Wolff HM, Seiffert T, Boddenberg A, et al. Drug release characteristics of rotigotine transdermal system. Presented at: 33rd Annual Meeting and Exposition of the Controlled Release Society; Vienna, Austria; 2006
   Google Scholar
• Baldwin CM, Keating GM. Rotigotine transdermal patch: are view of its use in the management of Parkinson’s disease. CNS Drugs. 2007;21:1039–1055.
   PubMed Web of Science ®Google Scholar
• Bogan RK. From bench to bedside: an overview of rotigotine for the treatment of restless legs syndrome. ClinTher. 2014;36:436–455.
   Google Scholar
• Cawello W, Kim SR, Braun M, et al. Pharmacokinetics, safety, and tolerability of rotigotine transdermal system in healthy Japanese and Caucasian subjects following multiple-dose administration. Eur J Drug MetabPharmacokinet. 2015 Mar 13. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Kim BH, Yu KS, Jang IJ, et al. Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy korean volunteers. ClinTher. 2015;37:902–912.
   Google Scholar
• Millan M, Maiofiss L, Cussac D, et al. Differential action of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. Jept.. 2002;303:791–804.
   Google Scholar
• Van Der Weide J, Tendijck ME, Tepper PG, et al. The enantiomers of the D-2 dopamine receptor agonist N-0437 discriminate between pre- and postsynaptic dopamine receptors. Eur J Pharmacol. 1988;146:319–326.
   PubMed Web of Science ®Google Scholar
• Van Der Weide J, De Vries JB, Tepper PG, et al. Pharmacological profiles of three new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734. Eur J Pharmacol. 1986;125:273–282.
   PubMed Web of Science ®Google Scholar
• Timmerman W, Dubocovich ML, Westerink BH, et al. The enantiomers of the dopamine agonist N-0437: in vivo and in vitro effects on the release of striatal dopamine. Eur J Pharmacol. 1989;166:1–11.
   PubMed Web of Science ®Google Scholar
• Schmidt WJ, Lebsanft H, Heindl M, et al. Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements. J Neural Transm. 2008;115:1385–1392.
   PubMed Web of Science ®Google Scholar
• Stockwell KA, Scheller D, Rose S, et al. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction. Exp Neurol. 2009;219:533–542.
   PubMed Web of Science ®Google Scholar
• Oertel WH, Trenkwalder C, Zucconi M, et al. State of the art in restless legs syndrome: practice recommendations for treating restless legs syndrome. Mov Disord. 2007;22:S466–S475.
   Web of Science ®Google Scholar
• Garcia-Borreguero D, Stillman P, Benes H, et al. Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol. 2011;11:28.
   PubMed Web of Science ®Google Scholar
• Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996;19:205–213.
   PubMed Web of Science ®Google Scholar
• Ferini-Strambi L, Marelli S. Pharmacotherapy for restless legs syndrome. Expert OpinPharmacother. 2014;15:1127–1138.
   PubMed Web of Science ®Google Scholar
• Stiasny-Kolster K, Kohnen R, Schollmayer E, et al. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord. 2004;19:1432–1438.
   PubMed Web of Science ®Google Scholar
• Oertel WH, Beneš H, García-Borreguero D, et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med. 2008;9:228–239.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Benes H, Poewe W, et al. Efficacy of rotigotine for treatment of moderate to severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2008;7:595–604.
   PubMed Web of Science ®Google Scholar
• Hening WA, Allen RP, Ondo WG, et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord. 2010;25:1675–1683.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Ikeda J, Tomida T, et al. Daytime symptoms of restless legs syndrome–clinical characteristics and rotigotine effectiveness. Sleep Med. 2015;16:871–876.
   PubMed Web of Science ®Google Scholar
• Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005;165:1286–1292.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Hirata K, Hayashida K, et al. Efficacy, safety and risk of augmentation of rotigotine for treating restless legs syndrome. Prog Neuro-Psychopharmacology Biol Psychiatry. 2013;40:326–333.
   PubMed Web of Science ®Google Scholar
• Oertel WH, Benes H, Garcia-Borreguero D, et al. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. Sleep Med. 2008;9:865–873.
   PubMed Web of Science ®Google Scholar
• Högl B, Oertel WH, Stiasny-Kolster K, et al. Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch. BMC Neurol. 2010;10:1.
   PubMed Web of Science ®Google Scholar
• Dohin E, Högl B, Ferini-Strambi L, et al. Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1-3 mg/24 h for up to 5 years. Expert OpinPharmacother. 2013;14:15–25.
   PubMed Web of Science ®Google Scholar
• Song ML, Oldham MA, Park KM, et al. Comparison of impact of insomnia on depression and quality of life in restless legs syndrome/Willis–Ekbom disease and primary insomnia patients. Sleep Med. 2015;16:1403–1408.
   PubMed Web of Science ®Google Scholar
• Ferini-Strambi L, Walters AS, Sica D. The relationship among restless legs syndrome (Willis–Ekbom Disease), hypertension, cardiovascular disease, and cerebrovascular disease. J Neurol. 2014;261:1051–1068.
   PubMed Web of Science ®Google Scholar
• Oertel WH, Benes H, Garcia-Borreguero D, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med. 2010;11:848–856.
   PubMed Web of Science ®Google Scholar
• Cassel W, Kesper K, Bauer A, et al. Significant association between systolic and diastolic blood pressure elevations and periodic limb movements in patients with idiopathic restless legs syndrome. Sleep Med. 2016;17:109–120.
   PubMed Web of Science ®Google Scholar
• Oertel W, Bauer A, Cassel W, et al. Effect of rotigotine transdermal system on nocturnal blood pressure changes associated with periodic limb movements during sleep in patients with restless legs syndrome. Neurology. 2014 April 8;82(10): Supplement P5.268.
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Benes H, Partinen M. et al. Rotigotine in hemodialysis-associated restless legs syndrome: a randomized controlled trial. Am J Kidney Dis. 2016 Feb 2: pii: S0272-6386(16)00018-4. doi:10.1053/j.ajkd.2015.12.027. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Yang B, Xu J, Xue Q, et al. Non-pharmacological interventions for improving sleep quality in patients on dialysis: systematic review and meta-analysis. Sleep Med Rev. 2015;23:68–82.
   PubMed Web of Science ®Google Scholar
• Boroojerdi B, Wolff HM, Braun M, et al. Rotigotine transdermal patch for the treatment of Parkinson’s disease and restless legs syndrome. Drugs Today (Barc). 2010;46:483–505.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Shimizu T, Hirata K, et al. Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study. Sleep Med. 2013;14:1085–1091.
   PubMed Web of Science ®Google Scholar
• Stiasny-Kolster K, Berg D, Hofmann WE, et al. Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany. Sleep Med. 2013;14:475–481.
   PubMed Web of Science ®Google Scholar
• Liu GJ, Wu L, Wang SL, et al. Incidence of augmentation in primary restless legs syndrome patients may not be that high: evidence from a systematic review and meta-analysis. Medicine (Baltimore). 2016;95:e2504.
   PubMed Web of Science ®Google Scholar
• Beneš H, García-Borreguero D, Ferini-Strambi L, et al. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Med. 2012;13:589–597.
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Allen RP, Kohnen R, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a world association of sleep medicine-international restless legs syndrome study group consensus conference at the max planck institute. Sleep Med. 2007;8:520–530.
   PubMed Web of Science ®Google Scholar
• Elshoff JP, Timmermann L, Schmid M, et al. Comparison of the bioavailability and adhesiveness of different rotigotine transdermal patch formulations. Curr Med Res Opin. 2013;29:1657–1662.
   PubMed Web of Science ®Google Scholar
• Braun M, Elshoff JP, Andreas JO, et al. Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive. Br J Clin Pharmacol. 2009;68:386–394.
   PubMed Web of Science ®Google Scholar